Search

Your search keyword '"Hadaschik, Boris"' showing total 1,624 results
Start Over Author "Hadaschik, Boris"
1,624 results on '"Hadaschik, Boris"'

6. Bicenter validation of a risk model for the preoperative prediction of extraprostatic extension of localized prostate cancer combining clinical and multiparametric MRI parameters

Author

Ostau, Nicola Edith von, Handke, Analena Elisa, Wiesenfarth, Manuel, Albers, Peter, Antoch, Gerald, Noldus, Joachim, Reis, Henning, Cotarelo, Cristina, Preetz, Julia, Umutlu, Lale, Ingenwerth, Marc, Radtke, Jan Philipp, Hadaschik, Boris, Schimmöller, Lars, and Kesch, Claudia

Published
2024
Full Text
View/download PDF

11. Harninkontinenz nach radikaler Prostatektomie beim Prostatakarzinom – aktuelle Daten von 17.149 Patienten aus 125 zertifizierten Zentren

Author

Kowalski, Christoph, Sibert, Nora Tabea, Hammerer, Peter, Wesselmann, Simone, Feick, Günter, Carl, Ernst-Günther, Klotz, Theodor, Apel, Hendrik, Dieng, Sebastian, Nyarangi-Dix, Joanne, Knoll, Thomas, Reike, Moritz Johannes, Duwe, Gregor, Bartolf, Elisabeth, Steiner, Thomas, Borowitz, Rainer, Lümmen, Gerd, Seitz, Anna Katharina, Pfitzenmaier, Jesco, Aziz, Atiqullah, Brock, Marko, Berger, Frank Peter, Kaftan, Björn Theodor, Grube, Christian, Häfner, Tim, Hamza, Amir, Schmelz, Hans, Haas, Jürgen, Lenart, Sebastian, Lafita, Anselm, Sippel, Carsten, Winter, Alexander, Kedia, George, Hadaschik, Boris, Varga, Zoltan, Buse, Stephan, Richter, Matthias, Distler, Florian, Simon, Jörg, Wiegel, Thomas, Baltes, Stefan, Janitzky, Andreas, Sommer, Jens Peter, Hijazi, Sameh, Fülkell, Philipp, Harke, Nina N., Bolenz, Christian, Khalil, Christian, Breidenbach, Clara, Tennstedt, Pierre, and Burchardt, Martin

Published
2024
Full Text
View/download PDF

12. Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study

Author

Gafita, Andrei, Rauscher, Isabel, Weber, Manuel, Hadaschik, Boris, Wang, Hui, Armstrong, Wesley R, Tauber, Robert, Grogan, Tristan R, Czernin, Johannes, Rettig, Matthew B, Herrmann, Ken, Calais, Jeremie, Weber, Wolfgang A, Benz, Matthias R, Fendler, Wolfgang P, and Eiber, Matthias

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Urologic Diseases, Biomedical Imaging, Cancer, Aging, Prostate Cancer, Good Health and Well Being, Male, Humans, Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, Castration-Resistant, Prostate-Specific Antigen, Heterocyclic Compounds, 1-Ring, Lutetium, Retrospective Studies, Radiopharmaceuticals, Dipeptides, Treatment Outcome, metastatic castration-resistant prostate cancer, radionuclide, treatment, PSMA PET, interimPET, Lu-177-PSMA, 177Lu-PSMA, interim PET, radionuclide treatment, Nuclear Medicine & Medical Imaging, Clinical sciences
Abstract

Our objective was to develop version 1.0 of a novel framework for response evaluation criteria in prostate-specific membrane antigen (PSMA) PET/CT (RECIP) and a composite response classification that combines responses by prostate-specific antigen (PSA) measurements and by RECIP 1.0 (PSA + RECIP). Methods: This was an international multicenter, retrospective study. One hundred twenty-four men with metastatic castration-specific prostate cancer (mCRPC) who underwent 177Lu-PSMA therapy and received PSMA PET/CT at baseline and at an interim time point of 12 wk were included. Pairs of baseline interim PET/CT scans were interpreted by consensus among 3 masked readers for appearance of new lesions. Tumor lesions were segmented, and total PSMA-positive tumor volume (PSMA-VOL) was obtained. Appearance of new lesions and changes in PSMA-VOL were combined to develop RECIP 1.0, which included classifications of complete response (RECIP-CR: absence of any PSMA-ligand uptake on interim PET/CT), partial response (RECIP-PR: decline ≥ 30% in PSMA-VOL and no appearance of new lesions), progressive disease (RECIP-PD: increase ≥ 20% in PSMA-VOL and appearance of new lesions), and stable disease (RECIP-SD: any condition but RECIP-PR or RECIP-PD). Changes in PSA levels at 12 wk by Prostate Cancer Working Group Criteria 3 were recorded. PSA + RECIP results were defined as response (PSA decline ≥ 50% or RECIP-PR/CR) or progression (PSA increase ≥ 25% or RECIP-PD). The study's primary outcome measure was the prognostic value of RECIP 1.0 for overall survival (OS). The secondary outcome measure was the prognostic accuracy (C-index) of PSA + RECIP versus PSA responses. Results: Patients with RECIP-PD (n = 39; 8.3 mo) had a shorter OS than patients with stable disease (RECIP-SD) (n = 47; 13.1 mo; P < 0.001) or RECIP-PR (n = 38; 21.7 mo; P < 0.001). In identifying responders and progressors, PSA + RECIP had C-indices superior to those of PSA only: 0.65 versus 0.62 (P = 0.028) and 0.66 versus 0.63 (P = 0.044), respectively. Conclusion: PSMA PET/CT by RECIP 1.0 is prognostic for OS and can be used as a response biomarker to monitor early efficacy of 177Lu-PSMA in men with mCRPC. PSA + RECIP may be used as a novel composite endpoint in mCRPC clinical trial design.

Published
2022

13. Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study

Author

Flippot, Ronan, Telli, Tugce, Velev, Maud, Fléchon, Aude, De Vries-Brilland, Manon, Turpin, Léa, Bergman, Andries, Turco, Fabio, Mahammedi, Hakim, Fendler, Wolfgang P., Giraudet, Anne-Laure, Josset, Quentin, Montravers, Françoise, Vogel, Wouter, Gillessen, Silke, Berardi Vilei, Simona, Herrmann, Ken, Kryza, David, Paone, Gaetano, Hadaschik, Boris, Merlin, Charles, Dufour, Pierre-Alban, Bernard-Tessier, Alice, Naoun, Natacha, Patrikidou, Anna, Garcia, Camilo, Foulon, Stéphanie, Pagès, Arnaud, and Fizazi, Karim

Published
2024
Full Text
View/download PDF

14. Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study

Author

Karpinski, Madeleine J, Hüsing, Johannes, Claassen, Kevin, Möller, Lennart, Kajüter, Hiltraud, Oesterling, Florian, Grünwald, Viktor, Umutlu, Lale, Kleesiek, Jens, Telli, Tugce, Merkel-Jens, Anja, Hüsing, Anika, Kesch, Claudia, Herrmann, Ken, Eiber, Matthias, Hoberück, Sebastian, Meyer, Philipp T, Kind, Felix, Rahbar, Kambiz, Schäfers, Michael, Stang, Andreas, Hadaschik, Boris A, and Fendler, Wolfgang P

Published
2024
Full Text
View/download PDF

18. Profile of the multicenter cohort of the German Cancer Consortium’s Clinical Communication Platform

Author

Maier, Daniel, Vehreschild, Jörg Janne, Uhl, Barbara, Meyer, Sandra, Berger-Thürmel, Karin, Boerries, Melanie, Braren, Rickmer, Grünwald, Viktor, Hadaschik, Boris, Palm, Stefan, Singer, Susanne, Stuschke, Martin, Juárez, David, Delpy, Pierre, Lambarki, Mohamed, Hummel, Michael, Engels, Cäcilia, Andreas, Stefanie, Gökbuget, Nicola, Ihrig, Kristina, Burock, Susen, Keune, Dietmar, Eggert, Angelika, Keilholz, Ulrich, Schulz, Hagen, Büttner, Daniel, Löck, Steffen, Krause, Mechthild, Esins, Mirko, Ressing, Frank, Schuler, Martin, Brandts, Christian, Brucker, Daniel P., Husmann, Gabriele, Oellerich, Thomas, Metzger, Patrick, Voigt, Frederik, Illert, Anna L., Theobald, Matthias, Kindler, Thomas, Sudhof, Ursula, Reckmann, Achim, Schwinghammer, Felix, Nasseh, Daniel, Weichert, Wilko, von Bergwelt-Baildon, Michael, Bitzer, Michael, Malek, Nisar, Öner, Öznur, Schulze-Osthoff, Klaus, Bartels, Stefan, Haier, Jörg, Ammann, Raimund, Schmidt, Anja Franziska, Guenther, Bernd, Janning, Melanie, Kasper, Bernd, Loges, Sonja, Stilgenbauer, Stephan, Kuhn, Peter, Tausch, Eugen, Runow, Silvana, Kerscher, Alexander, Neumann, Michael, Breu, Martin, Lablans, Martin, and Serve, Hubert

Published
2023
Full Text
View/download PDF

21. Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors

Author

Pettinella, Francesca, Mariotti, Barbara, Lattanzi, Chiara, Bruderek, Kirsten, Donini, Marta, Costa, Sara, Marini, Olivia, Iannoto, Giulia, Gasperini, Sara, Caveggion, Elena, Castellucci, Monica, Calzetti, Federica, Bianchetto-Aguilera, Francisco, Gardiman, Elisa, Giani, Matteo, Dusi, Stefano, Cantini, Maurizio, Vassanelli, Aurora, Pavone, Denise, Milella, Michele, Pilotto, Sara, Biondani, Pamela, Höing, Benedikt, Schleupner, Marie Carolin, Hussain, Timon, Hadaschik, Boris, Kaspar, Cordelia, Visco, Carlo, Tecchio, Cristina, Koenderman, Leo, Bazzoni, Flavia, Tamassia, Nicola, Brandau, Sven, Cassatella, Marco A., and Scapini, Patrizia

Published
2024
Full Text
View/download PDF

22. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial

Author

Boschheidgen, Matthias, Albers, Peter, Schlemmer, Heinz-Peter, Hellms, Susanne, Bonekamp, David, Sauter, Andreas, Hadaschik, Boris, Krilaviciute, Agne, Radtke, Jan Philipp, Seibold, Petra, Lakes, Jale, Arsov, Christian, Gschwend, Jürgen E., Herkommer, Kathleen, Makowski, Marcus, Kuczyk, Markus A., Wacker, Frank, Harke, Nina, Debus, Jürgen, Körber, Stefan A., Benner, Axel, Kristiansen, Glen, Giesel, Frederik L., Antoch, Gerald, Kaaks, Rudolf, Becker, Nikolaus, and Schimmöller, Lars

Published
2024
Full Text
View/download PDF

23. Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol

Author

Calais, Jeremie, Zhu, Shaojun, Hirmas, Nader, Eiber, Matthias, Hadaschik, Boris, Stuschke, Martin, Herrmann, Ken, Czernin, Johannes, Kishan, Amar U, Nickols, Nicholas G, Elashoff, David, and Fendler, Wolfgang P

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Prostate Cancer, Aging, Patient Safety, Prevention, Biomedical Imaging, Cancer, Clinical Research, Urologic Diseases, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Antigens, Surface, Glutamate Carboxypeptidase II, Humans, Male, Positron Emission Tomography Computed Tomography, Prospective Studies, Prostatic Neoplasms, Radiotherapy Planning, Computer-Assisted, Prostate cancer, PSMA, PET/CT, Randomized phase 3 trial, Definitive radiation therapy, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Epidemiology
Abstract

BackgroundDefinitive radiation therapy (dRT) is an effective initial treatment of intermediate-risk (IR) and high-risk (HR) prostate cancer (PCa). PSMA PET/CT is superior to standard of care imaging (CT, MRI, bone scan) for detecting regional and distant metastatic PCa. PSMA PET/CT thus has the potential to guide patient selection and the planning for dRT and improve patient outcomes.MethodsThis is a multicenter randomized phase 3 trial (NCT04457245). We will randomize 312 patients to proceed with standard dRT (control Arm, n = 150), or undergo a PSMA PET/CT scan at the study site (both 18F-DCFPyL and 68Ga-PSMA-11 can be used) prior to dRT planning (intervention arm, n = 162). dRT will be performed at the treating radiation oncologist facility. In the control arm, dRT will be performed as routinely planned. In the intervention arm, the treating radiation oncologist can incorporate PSMA PET/CT findings into the RT planning. Androgen deprivation therapy (ADT) is administered per discretion of the treating radiation oncologist and may be modified as a result of the PSMA PET/CT results. We assume that approximately 8% of subjects randomized to the PSMA PET arm will be found to have M1 disease and thus will be more appropriate candidates for long-term systemic or multimodal therapy, rather than curative intent dRT. PET M1 patients will thus not be included in the primary endpoint analysis. The primary endpoint is the success rate of patients with unfavorable IR and HR PCa after standard dRT versus PSMA PET-based dRT. Secondary Endpoints (whole cohort) include progression free survival (PFS), metastasis-free survival after initiation of RT, overall survival (OS), % of change in initial treatment intent and Safety.DiscussionThis is the first randomized phase 3 prospective trial designed to determine whether PSMA PET/CT molecular imaging can improve outcomes in patients with PCa who receive dRT. In this trial the incorporation of PSMA PET/CT may improve the success rate of curative intent radiotherapy in two ways: to optimize patient selection as a biomarker and to personalizes the radiotherapy plan.Clinical trial registrationUCLA IND#147591 ○ Submission: 02.27.2020 ○ Safe-to-proceed letter issued by FDA: 04.01.2020 UCLA IRB #20-000378 ClinicalTrials.gov Identifier NCT04457245 . Date of Registry: 07.07.2020. Essen EudraCT 2020-003526-23.

Published
2021

24. Risk-adjusted Screening for Prostate Cancer—Defining the Low-risk Group by Data from the PROBASE Trial

Author

Krilaviciute, Agne, Kaaks, Rudolf, Seibold, Petra, de Vrieze, Maxime, Lakes, Jale, Radtke, Jan Philipp, Kuczyk, Markus, Harke, Nina N., Debus, Jürgen, Fink, Christoph A., Herkommer, Kathleen, Gschwend, Jürgen E., Meissner, Valentin H., Benner, Axel, Kristiansen, Glen, Hadaschik, Boris, Arsov, Christian, Schimmöller, Lars, Antoch, Gerald, Giesel, Frederik L., Makowski, Marcus, Wacker, Frank, Schlemmer, Heinz-Peter, Becker, Nikolaus, and Albers, Peter

Published
2024
Full Text
View/download PDF

29. Risk and predictors of adverse pathology after radical prostatectomy in patients diagnosed with IUSP 1–2 prostate cancer at MRI-targeted biopsy: a multicenter analysis

Author

Kesch, Claudia, Pantea, Vlad, Soeterik, Timo, Marquis, Alessandro, la Bombarda, Giulia, Morlacco, Allesandro, Barletta, Francesco, Radtke, Jan Philipp, Darr, Christopher, Preisser, Felix, Zattoni, Fabio, Marra, Giancarlo, van den Bergh, Roderik C. N., Hadaschik, Boris, and Gandaglia, Giorgio

Published
2023
Full Text
View/download PDF

31. Digital Rectal Examination Is Not a Useful Screening Test for Prostate Cancer

Author

Krilaviciute, Agne, Becker, Nikolaus, Lakes, Jale, Radtke, Jan Philipp, Kuczyk, Markus, Peters, Inga, Harke, Nina N., Debus, Jürgen, Koerber, Stefan A., Herkommer, Kathleen, Gschwend, Jürgen E., Meissner, Valentin H., Benner, Axel, Seibold, Petra, Kristiansen, Glen, Hadaschik, Boris, Arsov, Christian, Schimmöller, Lars, Giesel, Frederik Lars, Antoch, Gerald, Makowski, Marcus, Wacker, Frank, Schlemmer, Heinz-Peter, Kaaks, Rudolf, and Albers, Peter

Published
2023
Full Text
View/download PDF

32. Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement

Author

Deivasigamani, Sriram, Kotamarti, Srinath, Rastinehad, Ardeshir R., Salas, Rafael Sanchez, de la Rosette, J.J.M.C.H., Lepor, Herbert, Pinto, Peter, Ahmed, Hashim U., Gill, Inderbir, Klotz, Laurence, Taneja, Samir S., Emberton, Mark, Lawrentschuk, Nathan, Wysock, James, Feller, John F., Crouzet, Sebastien, Kumar M., Praveen, Seguier, Denis, Adams, Eric S., Michael, Zoe, Abreu, Andre, Jack Tay, Kae, Ward, John F., Shinohara, Katsuto, Katz, Aaron E., Villers, Arnauld, Chin, Joseph L., Stricker, Phillip D., Baco, Eduard, Macek, Petr, Ahmad, Ardalan E., Chiu, Peter K.F., Crawford, E. David, Rogers, Craig G., Futterer, Jurgen J., Rais-Bahrami, Soroush, Robertson, Cary N., Hadaschik, Boris, Marra, Giancarlo, Valerio, Massimo, Chong, Kian Tai, Kasivisvanathan, Veeru, Tan, Wei Phin, Lomas, Derek, Walz, Jochen, Guimaraes, Gustavo Cardoso, Mertziotis, Nikos I., Becher, Ezequiel, Finelli, Antonio, Kasraeian, Ali, Lebastchi, Amir H., Vora, Anup, Rosen, Mark A., Bakir, Baris, Arcot, Rohit, Yee, Samuel, Netsch, Christopher, Meng, Xiaosong, de Reijke, Theo M., Tan, Yu Guang, Regusci, Stefano, Benjamin, Tavya G.R., Olivares, Ruben, Noureldin, Mohamed, Bianco, Fernando J., Sivaraman, Arjun, Kim, Fernando J., Given, Robert W., Dason, Shawn, Sheetz, Tyler J., Shoji, Sunao, Schulman, Ariel, Royce, Peter, Shah, Taimur T., Scionti, Stephen, Salomon, Georg, Laguna, Pilar, Tourinho-Barbosa, Rafael, Aminsharifi, Alireza, Cathelineau, Xavier, Gontero, Paolo, Stabile, Armando, Grummet, Jeremy, Ledbetter, Leila, Graton, Margaret, Stephen Jones, J., and Polascik, Thomas J.

Published
2023
Full Text
View/download PDF

36. Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort

Author

Zschäbitz, Stefanie, Biernath, Nadine, Hilser, Thomas, Höllein, Alexander, Zengerling, Friedemann, Cascucelli, Jozefina, Paffenholz, Pia, Seidl, Daniel, Lutz, Christoph, Schlack, Katrin, Kingreen, Dorothea, Klümper, Niklas, Ivanyi, Philipp, von Amsberg, Gunhild, Heers, Hendrik, Roghmann, Florian, Tauber, Robert L., Cathomas, Richard, Hofer, Luisa, Niegisch, Günter, Klee, Melanie, Ehrenberg, Roland, Hassler, Andreas, Hadaschik, Boris A., Grünwald, Viktor, and Darr, Christopher

Published
2023
Full Text
View/download PDF

37. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)

Author

Seifert, Robert, Emmett, Louise, Rowe, Steven P., Herrmann, Ken, Hadaschik, Boris, Calais, Jeremie, Giesel, Frederik L., Reiter, Robert, Maurer, Tobias, Heck, Matthias, Gafita, Andrei, Morris, Michael J., Fanti, Stefano, Weber, Wolfgang A., Hope, Thomas A., Hofman, Michael S., Fendler, Wolfgang Peter, and Eiber, Matthias

Published
2023
Full Text
View/download PDF

38. Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET

Author

Farolfi, Andrea, Ilhan, Harun, Gafita, Andrei, Calais, Jeremie, Barbato, Francesco, Weber, Manuel, Afshar-Oromieh, Ali, Spohn, Fabian, Wetter, Axel, Rischpler, Christoph, Hadaschik, Boris, Pianori, Davide, Fanti, Stefano, Haberkorn, Uwe, Eiber, Matthias, Herrmann, Ken, and Fendler, Wolfgang Peter

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Urologic Diseases, Cancer, Biomedical Imaging, Aging, Prostate Cancer, Aetiology, 2.1 Biological and endogenous factors, Antigens, Surface, Glutamate Carboxypeptidase II, Humans, Image Processing, Computer-Assisted, Lymph Node Excision, Male, Positron-Emission Tomography, Prostatic Neoplasms, Salvage Therapy, Treatment Failure, PET, prostate cancer, PSA persistence, PSMA, salvage lymph node dissection, Nuclear Medicine & Medical Imaging, Clinical sciences
Abstract

The aim of this study was to analyze patterns of persistent versus recurrent or new PET lesions in a selected patient cohort with prostate-specific antigen (PSA) persistence after salvage lymph node dissection (SLND) and pre-procedure and post-procedure prostate-specific membrane antigen (PSMA) ligand PET. Methods: Sixteen patients were included in this multicenter study. The inclusion criteria were PSMA PET performed for biochemical recurrence before SLND (pre-SLND PET) and repeat PSMA PET performed for a persistently elevated PSA level (≥0.1 ng/mL) at least 6 wk after SLND (post-SLND PET). Image analysis was performed by 3 independent nuclear medicine physicians applying the molecular imaging TNM system PROMISE. Lesions were confirmed by histopathology, presence on correlative CT/MRI/bone scanning, or PSA response after focal therapy. Results: Post-SLND PET identified prostate cancer lesions in 88% (14/16) of patients with PSA persistence after SLND. Median PSA was 1.2 ng/mL (interquartile range, 0.6-2.8 ng/mL). Disease was confined to the pelvis in 56% of patients (9/16), and most of these men had common iliac (6/16, 38%) and internal iliac lymph node metastases (6/16, 38%). Extrapelvic disease was detected in 31% of patients (5/16). In pre- and post-SLND PET comparison, 10 of 16 had at least one lesion already detected at baseline (63% PET persistence), 4 of 16 had new lesions only (25% PET recurrence), and 2 had no disease on post-SLND PET. All validated regions (11 regions in 9 patients) were true-positive. Nine of 14 (64%) patients underwent repeat local therapies after SLND (7/14 radiotherapy, 2/14 surgery). Conclusion: SLND of pelvic nodal metastases was often not complete according to PSMA PET. About two thirds of patients had PET-positive nodal disease after SLND already seen on pre-SLND PSMA PET. Notably, about one quarter of patients had new lesions, not detected by presurgical PSMA PET.

Published
2020

39. Detection of Clinically Significant Prostate Cancer Using Targeted Biopsy with Four Cores Versus Target Saturation Biopsy with Nine Cores in Transperineal Prostate Fusion Biopsy: A Prospective Randomized Trial

Author

Saner, Yasemin Melisa, Wiesenfarth, Manuel, Weru, Vivienn, Ladyzhensky, Boris, Tschirdewahn, Stephan, Püllen, Lukas, Bonekamp, David, Reis, Henning, Krafft, Ulrich, Heß, Jochen, Kesch, Claudia, Darr, Christopher, Forsting, Michael, Wetter, Axel, Umutlu, Lale, Haubold, Johannes, Hadaschik, Boris, and Radtke, Jan Philipp

Published
2023
Full Text
View/download PDF

43. Prognostic PSMA-PET PROMISE nomograms for patients with prostate cancer.

Author

Fendler, Wolfgang Peter, primary, Karpinski, Madeleine J., additional, Hüsing, Johannes, additional, Claassen, Kevin, additional, Möller, Lennart, additional, Kajüter, Hiltraud, additional, Oesterling, Florian, additional, Grünwald, Viktor, additional, Umutlu, Lale, additional, Lanzafame, Helena, additional, Telli, Tugce, additional, Merkel-Jens, Anja, additional, Hüsing, Anika, additional, Kesch, Claudia, additional, Herrmann, Ken, additional, Stang, Andreas, additional, and Hadaschik, Boris A., additional

Published
2024
Full Text
View/download PDF

44. Subgroup analysis of real-world efficacy of enfortumab vedotin in patients with metastatic/locally advanced urothelial carcinoma from a European database.

Author

Darr, Christopher, primary, Klümper, Niklas, additional, Büttner, Thomas, additional, Holzwarth, Nina, additional, Biernath, Nadine, additional, Höllein, Alexander, additional, Niegisch, Guenter, additional, Seidl, Daniel, additional, Handke, Analena, additional, Paffenholz, Pia, additional, Schlack, Katrin, additional, Cathomas, Richard, additional, Erne, Eva, additional, Banek, Severine, additional, Tauber, Robert, additional, Casuscelli, Jozefina, additional, Seitz, Anna Katharina, additional, Hadaschik, Boris A., additional, Grünwald, Viktor, additional, and Zschaebitz, Stefanie, additional

Published
2024
Full Text
View/download PDF

45. Establishing medical intelligence - leveraging FHIR to improve clinical management

Author

Brehmer, Alexander, primary, Sauer, Christopher M., additional, Salazar, Jayson, additional, Hermann, Kelsey, additional, Kim, Moon, additional, Keyl, Julius, additional, Bahnsen, Fin H., additional, Frank, Benedikt, additional, Köhrmann, Martin, additional, Rassaf, Tienush, additional, Mahabadi, Amir-Abbas, additional, Hadaschik, Boris, additional, Darr, Christopher, additional, Herrmann, Ken, additional, Tan, Susanne, additional, Buer, Jan, additional, Brenner, Thorsten, additional, Reinhardt, Christian, additional, Nensa, Felix, additional, Gertz, Michael, additional, Egger, Jan, additional, and Kleesiek, Jens, additional

Published
2024
Full Text
View/download PDF

46. Prognostic Implications of68Ga-FAPI-46 PET/CT–Derived Parameters on Overall Survival in Various Types of Solid Tumors

Author

Watanabe, Masao, primary, Fendler, Wolfgang P., additional, Grafe, Hong, additional, Hirmas, Nader, additional, Hamacher, Rainer, additional, Lanzafame, Helena, additional, Pabst, Kim M., additional, Hautzel, Hubertus, additional, Aigner, Clemens, additional, Kasper, Stefan, additional, von Tresckow, Bastian, additional, Stuschke, Martin, additional, Kümmel, Sherko, additional, Lugnier, Celine, additional, Hadaschik, Boris, additional, Grünwald, Viktor, additional, Zarrad, Fadi, additional, Siveke, Jens T., additional, Herrmann, Ken, additional, and Weber, Manuel, additional

Published
2024
Full Text
View/download PDF

48. MP44-04 RAPN IN PATIENTS WITH CHRONIC KIDNEY DISEASE—A MULTICENTRIC ANALYSIS

Author

Katzendorn, Olga, primary, Fuhrmann, Christian, additional, Schiefelbein, Frank, additional, Schoen, Georg, additional, Wiesinger, Clemens, additional, Pfuner, Jacob, additional, Ubrig, Burkhard, additional, Gloger, Simon, additional, Nuhn, Philipp, additional, Eraky, Ahmed, additional, Wagner, Christian, additional, Ayanle, Abdirahman, additional, Kesch, Claudia, additional, Al-Nader, Mulham, additional, Hadaschik, Boris A., additional, Tabrizi, Pouriya Faraj, additional, Kuczyk, Markus A., additional, Siemer, Stefan, additional, Stöckle, Michael, additional, Zeuschner, Philip, additional, and Harke, Nina N., additional

Published
2024
Full Text
View/download PDF

49. Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic Literature Review

Author

Gartrell, Benjamin A., primary, Phalguni, Angaja, additional, Bajko, Paulina, additional, Mundle, Suneel D., additional, McCarthy, Sharon A., additional, Brookman-May, Sabine D., additional, De Solda, Francesco, additional, Jain, Ruhee, additional, Yu Ko, Wellam, additional, Ploussard, Guillaume, additional, and Hadaschik, Boris, additional

Published
2024
Full Text
View/download PDF

50. PD26-07 MRI-GUIDED ACTIVE SURVEILLANCE IN PATIENTS WITH ISUP 1 PROSTATE CANCER—A MULTI-INSTITUTIONAL VALIDATION OF THE DISCRIMINATION OF THE PRECISE SCORE

Author

Sushentsev, Nikita, primary, Wiesenfarth, Manuel, additional, Dixius, Martin, additional, Kastner, Christof, additional, Borkowetz, Angelika, additional, Platzek, Ivan, additional, Thomas, Christian, additional, Kesch, Claudia, additional, Umutlu, Lale, additional, Reis, Henning, additional, Rau, Tilmann, additional, Lenders, Lotte, additional, Spahn, Martin, additional, Boschheidgen, Matthias, additional, Antoch, Gerald, additional, Albers, Peter, additional, Barrett, Tristan, additional, Schimmöller, Lars, additional, Hadaschik, Boris, additional, and Radtke, Jan Philipp, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results